Loading
A phase 3 trial of Bempegaldesleukin, Sunitinib, Nivolumab and Cabozantinib in Renal cell carcinoma, run by Nektar Therapeutics, recorded as terminated on the registry.
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) is a phase 3 interventional study registered as NCT03729245 by Nektar Therapeutics, with 623 participants recorded, started 2018-12-18 and due to reach its primary completion in 2022-01-07. Interventions recorded: bempegaldesleukin, sunitinib, nivolumab, cabozantinib. Conditions recorded: Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma.
Linked to the drug Bempegaldesleukin because the registry names it among its interventions and Renal cell carcinoma among its conditions. Registry record only: no result has been read by an editor.
Shares Nektar Therapeutics, Bempegaldesleukin, Nivolumab and the tag pipeline.
Shares NKTR, Bempegaldesleukin, Nivolumab and the tag pipeline.
Shares Cabozantinib, Nivolumab and the tag pipeline.
Shares Sunitinib, Renal cell carcinoma and the tag pipeline.
Shares Sunitinib, Renal cell carcinoma and the tag pipeline.
Shares Cabozantinib, Nivolumab and the tag pipeline.
Shares Nivolumab and the tag pipeline.
Shares Sunitinib and the tag pipeline.